DUTCH PEERS Data Evaluate Newer-Generation DES at 3 Years


April 24, 2017—A report assessing the 3-year safety and efficacy of implanting newer-generation Resolute Integrity zotarolimus-eluting stents (ZES; Medtronic) versus Promus Element everolimus-eluting stents (EES; Boston Scientific Corporation) in the all-comers, investigator-initiated DUTCH PEERS trial was published online by Liefke C. van der Heijden, MD, et al in EuroIntervention.

The investigators concluded that the safety and efficacy of treating all-comers with newer-generation Resolute Integrity and Promus Element stents were found to be extended up to 3 years.

As summarized in EuroIntervention, the multicenter DUTCH PEERS trial randomly assigned a total of 1,811 all-comers patients to 1:1 treatment with ZES versus EES. A total of 1,293 patients (72%) were treated for complex lesions and 455 patients (25%) were treated for multiple lesions.

The primary endpoint of target vessel failure (TVF) is a composite of cardiac death, target vessel-related myocardial infarction, or target vessel revascularization. Adverse clinical events were independently adjudicated. Three-year follow-up data were obtained in 1,807 patients (99.8%, four withdrawals).

The investigators found that both the ZES and EES groups showed favorable outcomes with a similar incidence of TVF (10.7% vs 10.3%; log-rank P = .77) and the individual components thereof: cardiac death (3.2% vs 3.1%; log-rank P = .87), target vessel-related myocardial infarction (2.8% vs 2.2%; log-rank P = .44), and target vessel revascularization (6% vs 6.2%; log-rank P = .87). In addition, the incidence of definite or probable stent thrombosis was similar for patients treated with ZES versus EES (1.4% vs 1.1%; log-rank P = .66), reported the DUTCH PEERS investigators in EuroIntervention.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.